VivaGel® BV phase 3 results timing and commercialisation

4 July 2017

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced revised timing for results of its two pivotal VivaGel® BV phase 3 trials for the prevention of recurrent bacterial vaginosis – now expected to be available in late July/early August 2017. 

Read More

Starpharma today also released its July Shareholder Update, which can be viewed here

© Starpharma Holdings Limited 2017